Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25981491 | 0.94 | ALDH1A1 (0.58) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL3361808 | 0.90 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL5543236 | 0.87 | LMNA (0.62) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL11783251 | 0.86 | HTT (0.66) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL6741072 | 0.86 | LMNA (0.65) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL126974 | 0.86 | HTT (0.66) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL8274250 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| Acetic Acid SCHEMBL8324881 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| SCHEMBL2065470 | 0.85 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2ALDH1A1CTSLCTSB | |
| Hydrochloric Acid SCHEMBL8688569 | 0.84 | HTT (0.64) | LMNASMN1; SMN2ALDH1A1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285486-A | Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester | 南通敏言生物医药科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| CN-117285486-A | Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester | 南通敏言生物医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117285486-A | Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester | 南通敏言生物医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023018215-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| US-20210283132-A1 | DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007022241-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022241-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-5130322-A | CHROMAN DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-07-14 | — | — | US | disclosed |
| EP-0415065-A1 | Chroman derivatives | MERCK PATENT GmbH (DE) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | LMNA 1339/4885SMN1; SMN2 281/4885ALDH1A1 144/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | LMNA 1527/4885SMN1; SMN2 4306/4885ALDH1A1 1133/4885 |
| US-20210283132-A1 | DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF | BRAF, NRAS, MAP2K5 | LMNA 4080/4885SMN1; SMN2 2710/4885ALDH1A1 987/4885 |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | LMNA 4064/4885SMN1; SMN2 2557/4885ALDH1A1 1652/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | LMNA 2142/4885SMN1; SMN2 2487/4885ALDH1A1 4640/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | LMNA 1887/4885SMN1; SMN2 3177/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.